Nektar Therapeutics (NKTR) Earnings History
Net Loss32 years of earnings data (1994–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Nektar Therapeutics (NKTR) Earnings Overview
As of June 22, 2026, Nektar Therapeutics (NKTR) reported trailing twelve-month net income of -$158M, reflecting -12.1% year-over-year growth. The company earned $-6.39 per diluted share over the past four quarters, with a net profit margin of -297.1%.
Looking at the long-term picture, NKTR's historical earnings data spans multiple years. The company achieved its highest annual net income of $681M in fiscal 2018.
Nektar Therapeutics is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($349M net income, 22.7% margin), ARWR (-$301M net income, -0.2% margin), ALNY ($577M net income, 8.4% margin), NKTR has room to improve margins relative to the peer group. Compare NKTR vs HALO →
NKTR Earnings vs Peers
Earnings metrics vs comparable public companies
NKTR Historical Earnings Data (1994–2025)
32 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$164M | -37.9% | -$131M | $-9.73 | -297.1% | -236.8% |
| 2024 | -$119M | +56.9% | -$105M | $-8.68 | -120.9% | -106.9% |
| 2023 | -$276M | +25.0% | -$137M | $-21.79 | -306.3% | -152.5% |
| 2022 | -$368M | +29.7% | -$240M | $-29.51 | -400.0% | -261.0% |
| 2021 | -$524M | -17.9% | -$446M | $-42.90 | -514.0% | -437.8% |
| 2020 | -$444M | -0.9% | -$380M | $-37.33 | -290.6% | -248.5% |
| 2019 | -$441M | -164.7% | -$440M | $-37.80 | -384.5% | -383.9% |
| 2018 | $681M | +804.6% | $688M | $56.70 | 57.1% | 57.6% |
| 2017 | -$97M | +37.0% | -$60M | $-9.30 | -31.4% | -19.4% |
| 2016 | -$154M | -89.1% | -$113M | $-16.50 | -92.8% | -68.2% |
| 2015 | -$81M | -50.6% | -$29M | $-9.15 | -35.2% | -12.7% |
| 2014 | -$54M | +66.7% | -$16M | $-6.30 | -26.9% | -8.2% |
| 2013 | -$162M | +5.7% | -$120M | $-21.00 | -108.8% | -80.7% |
| 2012 | -$172M | -28.3% | -$141M | $-22.50 | -211.7% | -173.9% |
| 2011 | -$134M | -253.1% | -$124M | $-17.85 | -187.4% | -173.4% |
| 2010 | -$38M | +63.0% | -$28M | $-6.00 | -23.9% | -17.8% |
| 2009 | -$103M | -198.6% | -$95M | $-16.65 | -142.5% | -132.3% |
| 2008 | -$34M | -4.8% | -$83M | $-5.55 | -38.1% | -91.6% |
| 2007 | -$33M | +78.8% | -$36M | $-5.40 | -12.0% | -13.2% |
| 2006 | -$155M | +16.4% | -$159M | $-25.80 | -71.1% | -73.1% |
| 2005 | -$185M | -81.7% | -$183M | $-32.25 | -146.6% | -144.6% |
| 2004 | -$102M | -118.3% | -$74M | $-19.50 | -89.2% | -64.7% |
| 2003 | -$47M | +56.6% | -$66M | $-12.60 | -43.9% | -62.3% |
| 2002 | -$107M | +57.0% | -$100M | $-29.10 | -113.3% | -105.5% |
| 2001 | -$250M | -156.7% | -$257M | $-70.65 | -322.7% | -331.7% |
| 2000 | -$97M | -153.3% | -$66M | $-34.80 | -188.7% | -128.1% |
| 1999 | -$38M | -109.5% | -$40M | $-16.95 | -93.0% | -97.9% |
| 1998 | -$18M | -83.9% | -$22M | $-8.70 | -84.2% | -100.9% |
| 1997 | -$10M | +0.2% | -$14M | $-5.40 | -61.4% | -84.5% |
| 1996 | -$10M | -29.9% | -$12M | $-6.60 | -144.9% | -166.7% |
| 1995 | -$8M | -45.3% | -$9M | $-5.85 | -226.5% | -258.8% |
| 1994 | -$5M | - | -$6M | $-6.45 | -311.8% | -335.3% |
Download Data
Export NKTR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
32+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NKTR — Frequently Asked Questions
Quick answers to the most common questions about buying NKTR stock.
What is NKTR earnings per share (EPS)?
NKTR trailing twelve-month (TTM) diluted EPS is $-6.39, reflecting -12.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1994 to 2025 is available in the table on this page.
What is Nektar Therapeutics's net income?
Nektar Therapeutics (NKTR) trailing twelve-month net income is $-158M as of 2025. Earnings declined -12.1% year-over-year.
Is NKTR profitable?
NKTR is not currently profitable on a TTM basis, reporting a net loss of $-158M. Net margin is -297.1%. Investors should monitor for a return to profitability.
What is NKTR's earnings growth rate?
NKTR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1994 to 2025.
What are NKTR's profit margins?
Nektar Therapeutics net profit margin is -297.1%, operating margin is -236.8%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -217.9%.
Is NKTR growing earnings?
NKTR earnings are declining — EPS fell -12.1% year-over-year. TTM net income dropped to $-158M. This contrasts with the 5-year CAGR of N/A.
What was NKTR's best earnings year?
Nektar Therapeutics's highest annual net income on record is $681M, achieved in fiscal year 2018. Earnings history on this page spans 1994 to 2025 and includes all annual and quarterly figures.
What were NKTR's earnings last quarter?
NKTR's most recent reported quarter was Q1 2026. Net income was $-45M with diluted EPS of $-1.82. For a full breakdown of all quarters, see the quarterly earnings table on this page.